Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.42 |
| ▸ | THRA | P10827 | 9/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225821 | 0.93 | THRB (0.40) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3793749 | 0.91 | THRB (0.41) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3793748 | 0.88 | THRB (0.43) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3955909 | 0.86 | THRB (0.37) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3213016 | 0.85 | THRB (0.38) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3224353 | 0.85 | THRB (0.41) | THRBUSP2LMNARORCKDM4E | |
| SCHEMBL3226135 | 0.83 | MAPT (0.43) | THRBRORCKDM4EMAPTALDH1A1 | |
| SCHEMBL3233002 | 0.83 | RORC (0.55) | THRBTHRARORC | |
| SCHEMBL3223228 | 0.83 | THRB (0.36) | THRBTHRAUSP2LMNARORC | |
| SCHEMBL3222209 | 0.83 | THRB (0.36) | THRBTHRAUSP2LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420851-B2 | Selective TR-β 1 agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-04-16 | — | — | US | claimed |
| EP-2079678-B1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LTD (IN) | 2012-12-19 | — | — | EP | claimed |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-02-25 | — | — | US | claimed |
| EP-2079678-A2 | SELECTIVE TR-BETA 1 AGONIST | Cadila Healthcare Limited (IN) | 2009-07-22 | — | — | EP | claimed |
| WO-2008062469-A2 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| US-8420851-B2 | Selective TR-β 1 agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2079678-B1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LTD (IN) | 2012-12-19 | — | — | EP | disclosed |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-02-25 | — | — | US | disclosed |
| EP-2079678-A2 | SELECTIVE TR-BETA 1 AGONIST | Cadila Healthcare Limited (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008062469-A2 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885USP2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.